A drug combination tested for HR positive, HER2 negative breast cancer that has spread to the brain
Official title: Culmerciclib Plus Anlotinib and Endocrine Therapy for HR-Positive/HER2-Negative Metastatic Breast Cancer With Brain Metastases
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on .
The short version
This study is testing whether adding another drug to hormone therapy can help control breast cancer that has spread to the brain.
Read our full plain-language summary
What the trial team says
This study aims to evaluate the efficacy and safety of adding the anti-angiogenic agent anlotinib to the combination of the CDK2/4/6 inhibitor Culmerciclib and endocrine therapy in patients with HR+/HER2- breast cancer and brain metastases. Eligible patients present with newly diagnosed brain metastases or brain metastases that progressed following prior local therapy. It is hoped that this therapeutic combination can achieve disease control in these patients.
Key facts
- Registry number
- NCT07745257
- Stage of testing
- Phase 2
- Conditions studied
- HR-positive, HER2-negative Metastatic Breast Cancer With Brain Metastases
Where it is running
This trial lists 9 sites.
-
Guangdong
- Sun Yat-sen University Cancer Center (Guangzhou)
-
Hebei
- The Fourth Hospital of Hebei Medical University (Shijiazhuang)
-
Henan
- Anyang Tumor Hospital (Anyang)
- Henan Cancer Hospital (Zhengzhou)
-
Jiangsu
- Nanjing Drum Tower Hospital (Nanjing)
-
Jiangxi
- Nanchang People's Hospital (Nanchang)
-
Liaoning
- The Second Affiliated Hospital of Dalian Medical University (Dalian)
-
Sichuan
- Sichuan Provincial People's Hospital (Chengdu)
-
Zhejiang
- Zhejiang Cancer Hospital (Hangzhou)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.